Answers are grounded in this paper and cite their sources.
Demonstrates a bifunctional ligand that improves efficiency and stability in perovskite solar cells, indicating a new design approach.
Passivating engineering has emerged as one of the most important strategies for improving the performance and stability of perovskite solar cells (PSCs). However, most post-treatment or buried-in passivation approaches are depth-dependent, where separate agents target either bulk or interfacial defects, complicating film processing and limiting large-scale fabrication. Here, we report a bifunctional D-π-A passivating ligand, triphenylamine-furan-cyanoacrylic acid (TPA-FCA), which integrates a hydrophilic anchoring group with a bulky hydrophobic donor-π scaffold. Such bifunctional TPA-FCA self-organizes within the as-crystallized perovskite film, vertically segregating to both interfaces and simultaneously passivating the defects in the perovskite bulk and at adjacent interfaces. This characteristic enables TPA-FCA to suppress both nonradiative and charge-transport losses in the complete PSCs. Consequently, PSCs incorporating TPA-FCA deliver a champion efficiency of 26.56% (26.37% certified) together with remarkable operational stability. Under continuous maximum power point tracking at 65 °C (ISOS-L-2), the unencapsulated TPA-FCA device maintains 90% of its initial efficiency after 1400 h (T₉₀ = 1400 h). Further fabrication of large-area (30 cm × 30 cm) perovskite submodules demonstrates the passivation efficacy of the TPA-FCA, yielding a certified efficiency of 21.93%. This work provides fundamental insights into self-organized ligands and demonstrates an applicable molecular design strategy for high-performance, stable, and scalable perovskite photovoltaics.
No takes yet. Share an insight, caveat, or question.
li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: